Christopher Ketcherside, MD
Ophthalmology · Overland Park, KSNPI 1952523334
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,109 of the $6,278 with a category attached, or 81.4%. 27 manufacturers reported payments, led by Alcon at 25.5% of the total.
Across 197 payments — averaging $31.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- Rxsight Inc$1K
- Dompe US, Inc.$388
- Glaukos Corporation$345
- Carl Zeiss Meditec USA, Inc.$300
- Johnson & Johnson Surgical Vision, Inc.$264
- plus $2K from 21 others
Across 3 payments — averaging $12,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$36K
What the payments were for
- Speaking & faculty fees$1,02616%
- Food & beverage$5,10981%
- Education$1132%
- Other$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 60 | $1,602 |
| Rxsight Inc | 12 | $1,321 |
| Dompe US, Inc. | 9 | $388 |
| Glaukos Corporation | 6 | $345 |
| Carl Zeiss Meditec USA, Inc. | 4 | $300 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $264 |
| Oyster Point Pharma, Inc. | 14 | $259 |
| Bausch & Lomb Americas Inc. | 13 | $258 |
| AbbVie | 8 | $254 |
| Sun Pharmaceutical Industries Inc. | 8 | $170 |
| Amgen(2 entities) | 8 | $157 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $145 |
| Kala Pharmaceuticals, Inc. | 7 | $133 |
| Coopervision Inc. | 2 | $113 |
| Tarsus Pharmaceuticals, Inc. | 4 | $106 |
| Biotissue Holdings Inc. | 3 | $84 |
| Novartis | 5 | $82 |
| The Cameron-ehlen Group, Inc. | 3 | $68 |
| Carl Zeiss Meditec, Inc. | 1 | $57 |
| Aerie Pharmaceuticals, Inc. | 2 | $45 |
| Thea Pharma Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $20 |
| Spark Therapeutics, Inc. | 1 | $18 |
| Sanofi | 1 | $18 |
| Eyepoint US, Inc. | 1 | $16 |
| Sight Sciences, Inc. | 1 | $16 |
| Harrow Eye, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$1,000
- Clareon$267
- Oxervate$187
- LUMERA 700$164
- Centurion$149
- Clareon PanOptix Pro$149
- AcrySof IQ PanOptix UV IOL$139
- RXSIGHT CONTACT LENS$132
- RXSIGHT INJECTOR CARTRIDGE$132
- RXSIGHT INJECTOR HANDPIECE$132
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$132
- LIGHT ADJUSTABLE LENS (LAL)$132
- AcrySof$126
How this compares
$6,278 in reported general payments places this provider in the 85th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 74 | $89,743 |
| Prednisolone Acetate | 617 | $22,064 |
| ProlensaBromfenac Sodium | 34 | $11,653 |
| Difluprednate | 100 | $8,864 |
| Bromfenac Sodium | 52 | $7,856 |
| BesivanceBesifloxacin Hcl | 28 | $6,184 |
| Loteprednol Etabonate | 30 | $5,679 |
| IlevroNepafenac | 15 | $5,299 |
| Famciclovir | 87 | $4,006 |
| BromsiteBromfenac Sodium | 12 | $2,768 |
| ValacyclovirValacyclovir Hcl | 38 | $2,640 |
| MoxifloxacinMoxifloxacin Hcl | 151 | $2,630 |
| Fluorometholone | 22 | $1,164 |
| ErythromycinErythromycin Base | 19 | $228 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $254 | $89,74374 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance, Loteprednol Etabonate | $145 | $23,51692 claims |
| NovartisIlevro | $82 | $5,29915 claims |
| Sun Pharmaceutical Industries Inc.Bromsite | $170 | $2,76812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 135 ophthalmology providers in Kansas.
Other ophthalmology in Overland Park
- Daniel DurrieOverland Park$974K
- John HunkelerOverland Park$218K
- Christopher PoleOverland Park$129K
- Jason StahlOverland Park$10K
- Selena FuOverland Park$5K
- Timothy CavanaughOverland Park$5K
- Johann OhlyOverland Park$4K
- Keith WarrenOverland Park$4K
- Austin AndersenOverland Park$3K
- Kristin Schmid BiggerstaffOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.